Today’s AI Top Pick: SPRO
7/24/2026 · Contrarian screen · a free sample of K3vl4r’s AI-curated picks.
AI-ranked from a screened shortlist, with entry strategy, targets, and risks.
View the live SPRO price forecast →
SPRO is the cleanest contrarian bounce setup in the entire pool. The stock is at $1.15 with an RSI of 19 (deeply oversold), a 14-day drawdown of -44.8%, and position_in_21bar_range of 0-7% across every timeframe — this is textbook exhausted selling, not a mid-trend breakdown. Every timeframe forecast is aggressively up: 1h +128.25%, 4h +129.78%, 1d +23.82% short / +84.81% mid / +88.02% long, and 1wk +78.78% short. Bullish probability = 1.0. This is the rarest kind of multi-timeframe alignment where 1h/4h/1d/1wk are all pointing up simultaneously from the low of the range. What makes SPRO the winner rather than a broken microcap is that the drawdown is being met with a concrete, material, positive catalyst: the July 15 Innovent IBI355 licensing deal worth up to $1.1B, plus the earlier Utebzi royalty deal that funds SP001 in-licensing. Against a $67M market cap, that headline is transformative — it directly refutes the 'broken thesis' interpretation of the drawdown. Fundamentals corroborate: fundamental_score 8, PE 4.76, fwdPe 1.73, ROE 35.12%, profit margin 27.82%, debt/equity 0.05, salesYoY +93.5%, epsNextY +331%, analyst target upside +244.8%. That is a rare fundamental profile at these depths. Why TODAY rather than wait: price is pinned at the 21-bar low across 1d and 1wk (pos_in_range = 0), meaning the pullback for a 'better entry' has effectively already happened. RSI 19 rarely persists more than a few sessions before a mean-reversion move. The 1h shows the first sign of stabilization (dd_from_21bar_high only -14.19% vs -49% on 1d), which historically marks the inflection where sellers exhaust. Waiting means paying up after the first 20-30% snapback. Risk is real (microcap Healthcare, prior -51% YTD, recom 3.0 = hold consensus), but the reward-to-risk is asymmetric: model implies 84%+ expected return, and a defined stop below the recent low keeps downside to ~15-18%.
- Microcap ($67M) Healthcare stock — liquidity gaps and 5-10% intraday swings are normal
- Analyst recom is 3.0 (hold), not a strong-buy consensus despite +244.8% target upside — Street is skeptical
- 1wk fc_long is only +30.11% (decelerating vs short-term), suggesting the bounce may be tactical not structural
- Short float 6.69% is modest but a failed bounce could trigger stop-loss cascade given tiny float
- Biotech binary risk: any negative update on SP001 in-licensing or IBI355 deal terms could re-crater the stock 30%+
| # | Symbol | Verdict | Score | Read |
|---|---|---|---|---|
| 1 | SPRO | BUY NOW | 9.3 | RSI 19, all timeframes screaming reversal, $1.1B Innovent deal catalyst, PE 4.76 — the cleanest contrarian setup on the board. |
| 2 | BESS | BUY NOW | 7.8 | Full 4-timeframe bullish alignment with +62-106% weekly forecast and a real Texas BESS project catalyst; fwdPe 2.44. |
| 3 | SPIR | BUY PULLBACK | 7.2 | Strong fundamentals (PE 7.33, ROE 100.58%), analyst upgrade, satellite launch catalyst — but 1h at 74% of range means wait for a dip to $10.50. |
| 4 | APP | BUY PULLBACK | 6.6 | PEG 0.43, ROE 266%, profitMargin 62.5% — high-quality dip, but 1wk fc_long is -69.2% which is a serious multi-timeframe divergence. |
| 5 | IBM | BUY PULLBACK | 6.4 | Blue-chip dip with 1d fc +28% mid, PE 18.34; but 1h is at 98.6% of range (do not chase) and 1wk fc_mid is -8.91%. |
| 6 | GTBP | BUY PULLBACK | 5.9 | Deep drawdown, +782% analyst target upside, all timeframes bullish — but ROE -1446% and no news catalyst make it speculative. |
| 7 | SST | BUY PULLBACK | 5.7 | Massive forecasts (1d +132% mid, 1wk +182% long) but fundamental_score -0.75 and no meaningful news; smaller size only. |
| 8 | AKTX | BUY PULLBACK | 5.6 | Maxim upgrade to Buy with $30 PT and preclinical collab, but 1h and 1d forecasts are negative — wait for the 4h forecast to lead price. |
| 9 | INV | BUY PULLBACK | 5.5 | Huge forecasts (1wk fc_long +294%) and PS 76 suggests story stock; recent CEO change adds uncertainty. |
| 10 | CRML | BUY PULLBACK | 5.4 | Rare earths thesis with 4h/1d/1wk bullish forecasts, but the July 21 'disregard prior press release' headline is a red flag. |
| 11 | IONQ | BUY PULLBACK | 5.3 | Quantum leader with strong 1d/mid forecasts, but 1wk fc_long -50% and 1h fc_short slightly negative — wait for confirmation. |
| 12 | ATER | BUY PULLBACK | 5.2 | -58% dd on 4h, 1354% target upside, but pending asset sale and 6.74M resale prospectus is dilution overhang. |
| 13 | CALC | BUY PULLBACK | 5.1 | 1d fc_mid +254%, FDA clearance to proceed on Auxora is positive, but $49M private placement is dilutive. |
| 14 | MBLY | BUY PULLBACK | 5.1 | PEG 1.05, strong Q2 print, all timeframes bullish 1h-1d, but 1wk fc_mid -26% caps swing-trade upside. |
| 15 | TEM | BUY PULLBACK | 5.0 | Cathie Wood buying, salesYoY +69.8%, but $1.5B acquisition adds integration risk and shortFloat 31.7% is a squeeze/pain risk. |
| 16 | YCBD | WAIT | 4.9 | Positive Mexcor partnership news and forecasts all up, but tiny $6M cap and no timeframe pounding the table. |
| 17 | ACI | WAIT | 4.8 | Multi-tf bullish and RSI 23, but Wells Fargo downgrade the day of Q1 print is a real headwind; wait for reaction to settle. |
| 18 | CDZI | WAIT | 4.7 | BLM right-of-way + RIC Energy MoU are positives, but debt/equity 7.53, opMargin -166%, and pos_in_range 0 across all tfs suggests still capitulating. |
| 19 | LUCY | WAIT | 4.6 | Claude AI integration is a real catalyst, but warrant exercise dilution and near_term_bullish 0 means wait for 1h/4h to turn. |
| 20 | QS | BUY PULLBACK | 4.4 | All timeframes bullish and Honda partnership progressing, but recom 3.5 and -14% single-day drop on Jul 23 make it a knife-catch. |
| 21 | BTCT | WAIT | 4.3 | Explosive forecasts (1d fc_mid +140%) and 29.7% short float squeeze potential, but private placement dilution and $6.5M cap = casino. |
| 22 | GRRR | WAIT | 4.2 | $232M bond financings accelerate AI infra, but -32% drop on prior convertible is fresh in the tape; wait for basing. |
| 23 | TROLL-USD | WAIT | 4.0 | 1h/4h forecasts up but 1d forecast is -98% — the multi-timeframe disagreement is disqualifying. |
| 24 | TVRD | WAIT | 3.9 | 1wk fc_mid +724% is eye-popping, but ATM offering expansion + near_term_bullish 0 = wait for the ATM to clear. |
| 25 | ONMD | AVOID | 3.7 | 11.68M-share resale prospectus is fresh dilution overhang against a $34M cap — supply outweighs the bullish forecast. |
| 26 | SG | WAIT | 3.5 | Citi buy PT $10 is supportive, but 4h and 1wk forecasts turn negative in longer horizons and salesYoY is -1.55%. |
| 27 | XCH | AVOID | 3.3 | Only 1d timeframe available, 1h fc_short slightly negative, no news, fundamental_score -0.5 — thin thesis. |
| 28 | PMEC | AVOID | 3.1 | Small contract wins do not offset fundamental_score -2.5, instOwn 0.08%, and thin liquidity. |
| 29 | NN | AVOID | 3.0 | Fair value cut from analysts and PS 428, opMargin -1801% — a Zacks upgrade cannot overcome the fundamentals here. |
| 30 | LNAI | AVOID | 2.6 | PS 525, profitMargin -612568%, operMargin -46991% — the 1d fc_short -51.7% confirms the setup is broken despite deep drawdown. |
Get AI top picks & forecasts on any stock
K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord